SoftWave TRT

What SoftWave TRT does

SoftWave TRT (legal entity SoftWave Tissue Regeneration Technologies LLC) is a privately held medical device company headquartered in Alpharetta, Georgia, that develops, manufactures, and sells extracorporeal shockwave therapy (ESWT) systems under its flagship SoftWave Gold Li Series. The company's core technology uses high-voltage spark-initiated electrohydraulic acoustic waves reflected through a patented broad-focused parabolic applicator — the only broad-focused ESWT architecture on the market — to penetrate deep tissue with parallel wave dispersion while remaining comfortable for patients. The system holds FDA 510(k) clearances for connective tissue activation, chronic diabetic foot ulcer treatment, acute second-degree burn management, temporary pain relief, and temporary increase in blood flow, and is Health Canada licensed for tendinopathies.

The company sells capital equipment on a quote-based, multi-year contract basis to a distributed base of healthcare providers across orthopedic surgery, sports medicine, podiatry, urology, wound care, physical therapy, and regenerative medicine, with additional enterprise channels through a VA SSF Contract/Schedule Holder position and partnerships with professional sports organizations. Provider economics rely on cash-pay patient treatments rather than insurance reimbursement, supported by on-site training and certification. A wholly owned cardiology subsidiary (CRT) has been developing a patented cardio applicator for over a decade, culminating in the 2024 CAST-HF trial published in the European Heart Journal in collaboration with the Medical University of Innsbruck.

Commercially, SoftWave derives revenue primarily from one-time device sales, with provider-side recurring treatment revenue accruing to its customers. The company holds 4 U.S. patents issued July 19, 2022, is recognized by the ISMST internationally, and lists Mayo Clinic, UCLA Health, UCSF, UPMC, Northwestern Medicine, Jefferson Health, Piedmont Health, and UCI Health among named reference accounts. In March 2026, the founder-led organization brought on MedTech operator Eric Finkelman as COO to lead operational scale and enterprise infrastructure, signaling a transition from research-driven niche operator to commercial scale-up.

Name

SoftWave TRT

Legal name

SoftWave Tissue Regenerations Technologies LLC

Website

https://softwavetrt.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

SoftWave TRT is a private Alpharetta, Georgia medical device company that develops and sells patented broad-focused electrohydraulic shockwave therapy systems to orthopedic, urology, wound care, physical therapy, VA, and professional sports providers.

Ownership category

akta.pro rank

Product category

Medical Devices (Shockwave Therapy Equipment)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

akta.pro secondary industry

Negative Pressure Wound Therapy (NPWT) Systems & Accessories (HLAHALAB)

Keywords

• Shockwave therapy devices
• Medical device manufacturing
• Tissue regeneration technology
• Electrohydraulic medical devices
• Regenerative medicine equipment

Headquarters

HQ city

Alpharetta

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Sale of SoftWave Gold Li Series shockwave therapy devices to healthcare providers including hospitals, clinics, and private practices. Devices are capital equipment purchases with on-site training and support included.
2. Treatment Services (Provider Revenue): Healthcare providers purchase the device and generate revenue through patient treatments. Treatments are cash-pay services not typically covered by insurance.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

SoftWave TRT designs, manufactures, and sells the SoftWave Gold Li Series, a patented broad-focused extracorporeal shockwave therapy (ESWT) device that uses electrohydraulic spark-initiated acoustic waves and a parabolic reflector to deliver true shockwaves for tissue regeneration, pain relief, and chronic wound healing. The device is FDA 510(k) cleared for connective tissue activation, chronic diabetic foot ulcers, acute second-degree burns, temporary pain relief, and temporary increase in blood flow, and is sold directly to healthcare providers and health systems with on-site training and certification included.

Product overview

SoftWave TRT offers a unified medical device product line centered on the SoftWave Gold Li Series, a patented broad-focused shockwave therapy system. The company provides electrohydraulic extracorporeal shockwave therapy (ESWT) technology for regenerative care across multiple medical specialties including orthopedics, urology, wound care, and sports medicine. The flagship device delivers spark-initiated acoustic shockwaves via a patented parabolic reflector, enabling treatment of conditions such as chronic diabetic foot ulcers, acute second-degree burns, musculoskeletal pain, and connective tissue activation. SoftWave TRT operates as a single-product medical device company with FDA clearances for specific clinical indications, offering providers an integrated solution for tissue regeneration therapy.

Differentiator

Problem solved

Functional benefit

Brands

• SoftWave Benefits: Patient-facing portal at softwavebenefits.com for patients seeking SoftWave therapy providers.

Products and services

• SoftWave Gold Li Series The SoftWave Gold Li Series is a patented broad-focused extracorporeal shockwave therapy (ESWT) device that uses electrohydraulic energy to deliver spark-initiated acoustic shockwaves via a parabolic reflector for tissue regeneration, pain relief, and healing across multiple medical indications. It is FDA 510(k) cleared for activation of connective tissue, treatment of chronic diabetic foot ulcers, acute second-degree burns, temporary pain relief, and temporary increase in blood flow, and is Health Canada licensed for tendinopathies and plantar fasciitis. It is sold to orthopedic surgeons, sports medicine physicians, podiatrists, urologists, wound care specialists, physical therapists, chiropractors, enterprise health systems, professional sports organizations, and Veterans Administration facilities, with on-site training and certification included.

Quantifiable outcome

• 88.3% of patients with chronic symptoms experienced improvement
• +4 more outcomes

Named customers9 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Medical University of Innsbruck / Dr. Johannes HolfeldcoreStrategic or Co-development Partner · 20 June 2024Research collaboration with Dr. Johannes Holfeld and team at Medical University of Innsbruck resulted in CAST-HF clinical trial published in European Heart Journal. The trial demonstrated cardiac shockwave therapy regenerates heart tissue after bypass surgery with 11.3% LVEF improvement vs 6.3% in control group.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BTL Group: Manufacturer of non-invasive medical and aesthetic devices, including shockwave therapy systems, radiofrequency, and electromagnetic devices. Directly competes with SoftWave across orthopedic, sports medicine, and rehabilitation indications with a strong U.S. sales presence.
• SANUWAVE Health: U.S.-listed company developing acoustic shockwave technology (dermaPACE, wound care applications) for advanced wound healing and regenerative medicine. Closest U.S. peer specifically competing in wound care indications including diabetic foot ulcers.
• Zimmer MedizinSysteme: German manufacturer of shockwave therapy (enPuls, Z Wave) and physical therapy devices. Direct competitor in the radial shockwave segment used by physical therapists, orthopedists, and sports medicine clinics across Europe and increasingly in the U.S.
• Electro Medical Systems (EMS): Swiss manufacturer of shockwave (Swiss DolorClast) and piezoelectric medical devices primarily serving orthopedics, sports medicine, urology, and dental markets. Closest peer in the radial/focused shockwave space competing head-to-head on orthopedic and sports medicine indications.
• Storz Medical: Swiss-based manufacturer of shockwave therapy devices (focused and radial) for orthopedics, urology (lithotripsy), cardiology, and aesthetics. Most direct global competitor to SoftWave in ESWT systems, with comparable depth-penetrating technology and broader international distribution.

Broad incumbents

• Integra LifeSciences: Diversified medical device company with regenerative technology and surgical/orthopedic franchises. Comparable as a peer in regenerative wound care and soft-tissue healing categories, and notably Integra acquired Misonix (ultrasonic/therapeutic devices), making it adjacent to SoftWave's energy-based therapeutic modality.
• Karl Storz SE & Co. KG: Parent company of Storz Medical and a global leader in endoscopy and surgical visualization. Comparable as an incumbent in operating-room capital equipment, particularly relevant to SoftWave's cardiac surgery and surgical-recovery applications where KARL STORZ has deep hospital relationships.
• DJO Global (Enovis / Chattanooga): Large orthopedic and physical therapy device manufacturer offering a broad portfolio including shockwave, electrotherapy, and rehabilitation equipment. Competes broadly with SoftWave in PT and orthopedic clinics but as part of a wider product portfolio rather than a focused shockwave specialist.

Emerging players

• Organogenesis: Commercial-stage regenerative medicine company focused on wound care (diabetic foot ulcers, burns) and surgical biologics. Comparable in the wound-care regeneration use case SoftWave addresses, particularly around diabetic foot ulcers, though using cellular and skin-substitute products rather than acoustic energy.
• Misonix (Integra subsidiary): Ultrasonic surgical and therapeutic device maker (now under Integra) used in neurosurgery, spine, and wound debridement. Comparable as a peer in energy-based therapeutic modalities aimed at tissue regeneration and surgical recovery, similar clinical end users.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SoftwaveTRT
• LinkedInlinkedin.com/company/softwavetrt

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SoftWave TRT